This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Haemonetics (HAE) Up 3.5% Since the Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.
Medical Product Stocks' Earnings on Feb 6: HAE, PAHC & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their quarterly reports on Feb 6.
Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.10 in first-quarter fiscal 2017, up 6.8% from the year-ago quarter.
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the buyout of Hennigsdorf, Germany-based InVivo Biotech Services GmbH.
Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging
by Zacks Equity Research
Bruker Corporation (BRKR) recently announced the acquisition of Bremen, Germany-based software solutions developer, SCiLS GmbH.
ResMed Achieves Key Milestone in Sleep-Disordered Breathing
by Zacks Equity Research
After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.
Illumina Fettered With Losses: Can It Bounce Back in 2017?
by Zacks Equity Research
During majority of the past one year, Illumina (ILMN) lagged the Zacks classified broader Medical - Biomedical and Genetics industry.
Masimo to Launch Advanced Monitoring Technologies in India
by Zacks Equity Research
Masimo (MASI) announced that it will launch Advanced Monitoring Technologies in the Indian market.
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3
by Zacks Equity Research
OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.
Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold?
by Zacks Equity Research
On Jan 2, 2017, Abaxis Inc. (ABAX), a leading manufacturer of portable medical and veterinary blood analysis systems, was upgraded to a Zacks Rank #3 (Hold).
Is Baxter Poised to Counter Low Cyclophosphamide Sales?
by Zacks Equity Research
On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions
by Zacks Equity Research
On Dec 27, CryoLife Inc. (CRY) was upgraded to a Zacks Rank #1 (Strong Buy).
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege
by Zacks Equity Research
Alere Inc. (ALR) announced that it has recently appealed at the Centers for Medicare & Medicaid Services for reinstatement of Medicare billing privilege.
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite
by Zacks Equity Research
NuVasive (NUVA) recently announced the receipt of approval from MHLW, for instruments used in the eXtreme Lateral Interbody Fusion (XLIF) procedure.
LabCorp: Covance Drug Prospects Bright, Competition Rife
by Zacks Equity Research
On Dec 28, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH).
ResMed: SDB Business Faces Risks, Reimbursement a Drag
by Zacks Equity Research
On Dec 27, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
Nutrisystem Declares Multi-Brand Marketing Approach for '17
by Zacks Equity Research
Nutrisystem Inc. (NTRI) announced that it will focus on a multi-brand marketing approach with two new distinct programs.
Myriad Genetics' Unit Releases Favorable Data on Vectra DA
by Zacks Equity Research
Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).
Cardiovascular Systems (CSII): Q1 Solid, Net Losses Linger
by Zacks Equity Research
On Dec 27, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).
Haemonetics' Plasma Group Impresses, Blood Center a Drag
by Zacks Equity Research
On Dec 12, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE).
Haemonetics Introduces Upgraded NextGen DMS 4 Software
by Zacks Equity Research
Haemonetics Corporation (HAE) recently unveiled upgraded NextGen DMS (Donor Management System) to augment plasma collection center operations.